It is still challenging to profit from Regenerative Medicine in spite of its high economical potential. On the one hand this is because of the complex conditions (classification, pre-clinic, clinical research, manufacturing, authorisation and reimbursement) and on the other hand known business models from the pharmaceutical and biotechnological industry as well as established strategies on development process cannot simply be adopted. Thus, an individual strategy must be generated for each approach.

The ATP offers consulting service regarding development strategy issues for scientists and founders who consider to translate their research output to cell- and tissue-based products as well as for established pharmaceutical and biotechnological companies.

After respectable analysis of the project the ATP prepares together with the client an individual strategy.